Poolbeg Pharma: Further data shows POLB001 potential in cancer CRS
Key highlights from today's POLB RNS include: - Efficacy is demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model - New data strengthens and facilitates the...